Skip to content

ADXN

Addex Therapeutics Ltd.

NASDAQ · Healthcare · Biotechnology · CH

$3.07
+6.15%
Ask drillr

Year over year

Reported trailing growth

Revenue
-48.1%
EBITDA
+5.6%
EBIT
-7.9%
EPS
+27.0%
Free cash flow
-64.8%
Operating cash flow
-64.9%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
-72.4%
EBITDA
-47.1%
EBIT
-2.2%
Net income
—
EPS
—
Free cash flow
+61.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026